Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares
February 26 2018 - 7:30AM
Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today
announced that the underwriters of its previously announced
underwritten public offering of 5,000,000 ordinary shares have
partially exercised their option to purchase an additional 255,683
ordinary shares from the Company at $6.75 per share, bringing total
gross proceeds from this offering to approximately $35.5 million
before deducting underwriting discounts and commissions and other
offering expenses payable by the Company. The partial exercise of
the underwriters’ option is expected to close on or about February
27, 2018 subject to satisfaction of customary closing conditions.
Cantor Fitzgerald & Co. is acting as the
sole bookrunner for the offering. JMP Securities LLC is acting as
the lead manager for the offering. Oppenheimer & Co. Inc. is
acting as lead co-manager and H.C. Wainwright & Co. is acting
as co-manager for the offering.
A shelf registration statement relating to the
ordinary shares was previously filed with the SEC and declared
effective on May 8, 2017. A final prospectus supplement and
accompanying prospectus relating to the offering were filed with
the SEC on January 26, 2018 and are available on the SEC’s website
located at http://www.sec.gov. Copies of the final prospectus
supplement and accompanying prospectus may be obtained from Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave.,
6th Floor, New York, New York 10022 or by e-mail at
prospectus@cantor.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of the prospectus supplement
and accompanying prospectus forming a part of the effective
registration statement.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs. Strongbridge's commercial portfolio within its rare
neuromuscular and rare endocrine franchises includes Keveyis®
(dichlorphenamide), the first and only FDA-approved treatment for
hyperkalemic, hypokalemic, and related variants of primary periodic
paralysis, and Macrilen™ (macimorelin), the first and only
FDA-approved oral drug indicated for the diagnosis of adult growth
hormone deficiency. The Company’s rare endocrine franchise also
includes a clinical-stage pipeline of therapies:
Recorlev™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in other
conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor RelationsUnited
States:The Trout Group Marcy Nanus +1 646-378-2927
mnanus@troutgroup.com
Europe:First HouseMitra Hagen Negård+47 21 04
62 19strongbridgebio@firsthouse.no
USA 900 Northbrook Drive Suite 200 Trevose,
PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024